MED13

Across TCGA pan-cancer cohorts, MED13 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MED13 data layer compared with 27 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MED13 Mutation is associated with better overall survival. In most high-consensus cancer types, elevated MED13 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

UCEC, SKCM, and GBM are the cancer types where MED13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	II,III,IV	0.955	0.442	.002	36	view →
SKCM	OS	Median	All	0.423	0.790	<.001	9	view →
GBM	OS	Median	All	0.104	0.415	.024	6	view →
BLCA	OS	Median	II,III,IV	0.755	0.400	.032	6	view →
LUSC	DFS	Median	III,IV	0.079	0.751	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MED13–UCEC (OS)

Open the UCEC breakdown →